SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1991 |
Sector | Life Science |
Employees | 2,700 |
Revenue | 753M USD (2023) |
Myriad is a molecular diagnostic company discovers and commercialize a transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad was founded in 1991 and is based in Salt Lake City, Utah.
DEAL STATS | # |
---|---|
Overall | 5 of 6 |
Sector (Healthcare Services) | 1 of 1 |
Type (Add-on Acquisition) | 4 of 4 |
State (California) | 2 of 2 |
Country (United States) | 4 of 5 |
Year (2018) | 1 of 1 |
Size (of disclosed) | 1 of 5 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-08-03 |
Assurex Health
Mason, Ohio, United States Assurex Health, Inc. is an informatics-based precision medicine company providing treatment decision support to healthcare providers for mental health. Assurex Health’s lead product, GeneSight® Psychotropic, evaluates 12 genes known to play a significant role in psychotropic drug response, and utilizing a proprietary combinatorial pharmacogenomics approach called CPGx, assigns patients into one of over 300,000 unique composite phenotypes. |
Buy | $225M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-04-27 |
Myriad myPath Melanoma
Salt Lake City, Utah, United States Myriad myPath Melanoma is a clinically validated GEP test designed to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. |
Sell | $33M |